![]() |
Name |
(3S)-3,8-dihydroxy-6,7-dimethyl-α-tetralone
|
Molecular Formula | C12H14O3 | |
IUPAC Name* |
3,8-dihydroxy-6,7-dimethyl-3,4-dihydro-2H-naphthalen-1-one
|
|
SMILES |
Cc1cc2c(c(O)c1C)C(=O)CC(O)C2
|
|
InChI |
InChI=1S/C12H14O3/c1-6-3-8-4-9(13)5-10(14)11(8)12(15)7(6)2/h3,9,13,15H,4-5H2,1-2H3/t9-/m0/s1
|
|
InChIKey |
ZILQDHDHXVYIDB-VIFPVBQESA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 206.24 | ALogp: | 1.5 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 57.5 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.682 |
Caco-2 Permeability: | -4.674 | MDCK Permeability: | 0.00001170 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.685 |
Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.253 |
30% Bioavailability (F30%): | 0.029 |
Blood-Brain-Barrier Penetration (BBB): | 0.897 | Plasma Protein Binding (PPB): | 82.96% |
Volume Distribution (VD): | 0.838 | Fu: | 17.52% |
CYP1A2-inhibitor: | 0.724 | CYP1A2-substrate: | 0.802 |
CYP2C19-inhibitor: | 0.093 | CYP2C19-substrate: | 0.733 |
CYP2C9-inhibitor: | 0.035 | CYP2C9-substrate: | 0.586 |
CYP2D6-inhibitor: | 0.035 | CYP2D6-substrate: | 0.32 |
CYP3A4-inhibitor: | 0.049 | CYP3A4-substrate: | 0.321 |
Clearance (CL): | 14.693 | Half-life (T1/2): | 0.534 |
hERG Blockers: | 0.017 | Human Hepatotoxicity (H-HT): | 0.126 |
Drug-inuced Liver Injury (DILI): | 0.399 | AMES Toxicity: | 0.112 |
Rat Oral Acute Toxicity: | 0.429 | Maximum Recommended Daily Dose: | 0.544 |
Skin Sensitization: | 0.549 | Carcinogencity: | 0.557 |
Eye Corrosion: | 0.007 | Eye Irritation: | 0.949 |
Respiratory Toxicity: | 0.643 |